Market Overview

UPDATE: Bank of America Initiates Intercept Pharmaceuticals at Buy on Regulatory Outlook

Share:
Related ICPT
Will Intercept Pharma Outperform? These Analysts Think So
Earnings Scheduled For March 2, 2015
How Alan Leong Of BioWatch News Keeps Successful Biotech Investing Simple (Seeking Alpha)

Bank of America initiated coverage on Intercept Pharmaceuticals (NASDAQ: ICPT) with a Buy rating and a $29 price objective.

Bank of America noted, "We are initiating coverage of Intercept pharmaceuticals (ICPT) with a Buy rating and DCF derived $29 PO. ICPT is a development stage pharmaceutical company focused on bile acid derived therapeutics. The company's lead product is OCA, a bile acid derivative, for the treatment of a rare autoimmune liver disease, primary billiary cirrhosis (PBC). We expect OCA will report positive Phase 3 trial results (2014). Our PO incorporates a heavier than normal risk adjustment for US approval pending additional clarity on the regulatory pathway in 2013; success in additional indications (e.g. portal hypertension) represent upside to our PO."

Intercept Pharmaceuticals closed at $20.00 on Friday.

Latest Ratings for ICPT

DateFirmActionFromTo
Jan 2015Deutsche BankMaintainsBuy
Dec 2014CitigroupMaintainsBuy
Dec 2014Bank of AmericaReinstatesBuy

View More Analyst Ratings for ICPT
View the Latest Analyst Ratings

Posted-In: Bank of AmericaAnalyst Color Initiation Pre-Market Outlook Analyst Ratings

 

Related Articles (ICPT)

Around the Web, We're Loving...